Precision oncology revolution: CRISPR-Cas9 and PROTAC technologies unleashed

Area of Science:

• Oncology
• Biotechnology
• Genetics

Background:

• Cancer remains a significant global health challenge, necessitating innovative therapeutic strategies.
• Precision oncology aims to target specific molecular drivers of cancer, improving efficacy and reducing side effects.
• Conventional therapies often struggle with "undruggable" targets and off-target toxicities.

Purpose of the Study:

• To review the current status and clinical implications of CRISPR-Cas9 gene editing and PROTAC targeted protein degradation in precision oncology.
• To compare the designs, potential, and limitations of CRISPR and PROTAC technologies.
• To explore the synergistic potential of combining these groundbreaking approaches.

Main Methods:

• Review of CRISPR-Cas9 gene editing technology for precise DNA modification.
• Review of PROTAC (PROteolysis TArgeting Chimeras) technology for targeted protein degradation.
• Analysis of preclinical and clinical trial data for both technologies in cancer treatment.

Main Results:

• CRISPR-Cas9 offers precise, efficient, and adaptable gene modification with diagnostic potential.
• PROTACs provide orally administrable, tissue-specific protein degradation with broad targeting capabilities.
• Both technologies demonstrate significant potential in preclinical studies and promising clinical trial data.

Conclusions:

• CRISPR and PROTAC technologies represent revolutionary advances in precision oncology.
• Their application is context-dependent, based on specific molecular mechanisms of cancer.
• These complementary technologies hold potential for synergistic use, expanding therapeutic options.